Intrahepatic Cholestasis of Pregnancy Management

Diagnosis and Risk Stratification

• Diagnosis is based on maternal pruritus, elevated serum bile acids ≥11 μmol/L, elevated liver enzymes, and exclusion of other causes of liver dysfunction, as recommended by the American College of Obstetricians and Gynecologists 1, 2
• Risk stratification is based on total serum bile acid (TSBA) levels, with categories including low (<40 μmol/L), moderate (40-99 μmol/L), and high (≥100 μmol/L) risk, corresponding to minimal, 0.3%, and 3.4% stillbirth risk, respectively, as supported by multiple studies 1, 2

• The following table summarizes the risk stratification:

  Bile Acid Level	Risk Category	Stillbirth Risk
  <40 μmol/L	Low	Minimal
  40-99 μmol/L	Moderate	0.3%
  ≥100 μmol/L	High	3.4%	[1, 2]

Treatment

• The American College of Obstetricians and Gynecologists recommends ursodeoxycholic acid (UDCA) as first-line treatment, with a dosage of 10-15 mg/kg/day divided into 2-3 doses, and typical regimens of 300 mg 2-3 times daily or 500 mg twice daily, as supported by multiple studies 1, 3, 2, 4
• UDCA significantly improves maternal pruritus, reduces total bile acid levels, and improves liver function tests, with potential benefits in reducing spontaneous preterm birth and stillbirth risk, as supported by multiple studies 1, 2
• For persistent symptoms despite UDCA, rifampicin (300-600 mg daily) or anion exchange resins (cholestyramine 4-8 g/day) may be considered, with monitoring for hepatotoxicity and vitamin K deficiency, respectively, as recommended by the European Association for the Study of the Liver and supported by multiple studies 2, 1, 5
• S-adenosyl-L-methionine may have additive effects with UDCA, as supported by multiple studies 5, 1
• Supportive measures include mild soaps, lukewarm water for bathing, topical emollients, cool compresses, and loose-fitting cotton clothing, as supported by multiple studies 5, 3
• Low to mid-potency topical corticosteroids can be used for symptomatic relief of mild to moderate pruritus, but extensive use of high-potency corticosteroids should be avoided due to the risk of low birth weight, as supported by multiple studies 5
• Antihistamines (e.g., diphenhydramine or hydroxyzine) may provide limited benefit but can help with sleep, as supported by multiple studies 1

Monitoring and Delivery

• The American College of Obstetricians and Gynecologists recommends repeat TSBA and liver function tests every 2 weeks until 32 weeks gestation, then weekly until delivery, with more intensive fetal surveillance for patients with bile acids ≥40 μmol/L, as supported by multiple studies 2, 1, 3, 4
• Coagulation parameters should be monitored, especially if using cholestyramine, as supported by multiple studies 2, 1
• Vitamin K deficiency should be corrected if present, particularly in patients with steatorrhea or those using anion exchange resins, as supported by multiple studies 2, 4
• Antenatal fetal surveillance should begin at diagnosis, with more intensive monitoring for patients with bile acids ≥40 μmol/L, as supported by multiple studies 1, 3, 4
• Delivery should be considered at 38-39 weeks for bile acids <40 μmol/L, 37-38 weeks for bile acids 40-99 μmol/L, and 36 weeks for bile acids ≥100 μmol/L, as supported by multiple studies 1, 3, 4

• The recommended delivery times are summarized in the following table:

  Bile Acid Level	Recommended Delivery Time
  ≥100 μmol/L	36 weeks
  40-99 μmol/L	37-38 weeks
  <40 μmol/L	38-39 weeks	[1, 3, 4]

Postpartum Care

• UDCA can be stopped at delivery, but if symptoms persist, it should be tapered over 2-4 weeks post-delivery, as supported by multiple studies 2
• Bile acids and liver enzymes should return to normal within 3 months, and if abnormalities persist beyond 6 weeks postpartum, underlying liver disease should be investigated, as supported by multiple studies 2, 5, 3
• Patients with complete normalization of liver function tests should have a second follow-up after 2-3 years, due to increased risk for hepatobiliary and immune-mediated diseases, as recommended by the European Association for the Study of the Liver (EASL) 6
• Lifelong ursodeoxycholic acid (UDCA) can be considered for patients with a confirmed class 4/class 5 ABCB4 variant and serum liver tests that do not normalize, as recommended by the EASL 6
• Genetic screening should be considered if family history of hepatobiliary disease, early onset, or severe disease, as recommended by the EASL 6

Complications and Associations

• Women with intrahepatic cholestasis of pregnancy have an increased risk of preeclampsia (aOR 2.62), as supported by multiple studies 1
• Multidisciplinary management involving maternal-fetal medicine and hepatology is recommended for severe cases, as supported by multiple studies 1, 2
• Patients with severe cholestasis, recurrent cholestasis, or early onset cholestasis should be considered for genetic testing for variants in bile acid transport proteins, as recommended by the EASL 6
• Patients with cholestasis have a 45-70% recurrence rate in subsequent pregnancies, making counseling about recurrence risk essential, as supported by the EASL 6
• Persistent abnormalities beyond 6 weeks postpartum may indicate underlying chronic liver disease, genetic variants affecting bile acid transport, or higher risk for future hepatobiliary diseases, as supported by multiple studies 5, 3, 2